• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单克隆抗体工程和设计调节 FcRn 活性:全面综述。

Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review.

机构信息

Service de Médecine Interne Immunologie Clinique, CHU de Tours, F-37032 Tours, France.

EA7501, GICC, Faculté de Médecine, Université de Tours, F-37032 Tours, France.

出版信息

Int J Mol Sci. 2022 Aug 24;23(17):9604. doi: 10.3390/ijms23179604.

DOI:10.3390/ijms23179604
PMID:36077002
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9455995/
Abstract

Understanding the biological mechanisms underlying the pH-dependent nature of FcRn binding, as well as the various factors influencing the affinity to FcRn, was concurrent with the arrival of the first recombinant IgG monoclonal antibodies (mAbs) and IgG Fc-fusion proteins in clinical practice. IgG Fc-FcRn became a central subject of interest for the development of these drugs for the comfort of patients and good clinical responses. In this review, we describe (i) mAb mutations close to and outside the FcRn binding site, increasing the affinity for FcRn at acidic pH and leading to enhanced mAb half-life and biodistribution, and (ii) mAb mutations increasing the affinity for FcRn at acidic and neutral pH, blocking FcRn binding and resulting, in vivo, in endogenous IgG degradation. Mutations modifying FcRn binding are discussed in association with pH-dependent modulation of antigen binding and (iii) anti-FcRn mAbs, two of the latest innovations in anti-FcRn mAbs leading to endogenous IgG depletion. We discuss the pharmacological effects, the biological consequences, and advantages of targeting IgG-FcRn interactions and their application in human therapeutics.

摘要

理解 FcRn 结合的 pH 依赖性的生物学机制,以及影响与 FcRn 亲和力的各种因素,与第一批重组 IgG 单克隆抗体(mAbs)和 IgG Fc 融合蛋白进入临床实践是同时发生的。IgG Fc-FcRn 成为开发这些药物的一个核心关注点,以提高患者的舒适度和获得良好的临床反应。在这篇综述中,我们描述了(i)接近和远离 FcRn 结合位点的 mAb 突变,增加了酸性 pH 下对 FcRn 的亲和力,导致 mAb 半衰期和生物分布的增强,以及(ii)增加了 mAb 在酸性和中性 pH 下对 FcRn 的亲和力,阻断 FcRn 结合,导致体内内源性 IgG 降解的突变。我们讨论了与 pH 依赖性抗原结合调节相关的 FcRn 结合修饰突变,以及(iii)抗 FcRn mAbs,这是抗 FcRn mAbs 的最新创新中的两种,导致内源性 IgG 耗竭。我们讨论了靶向 IgG-FcRn 相互作用的药理学作用、生物学后果和优势,及其在人类治疗学中的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e00/9455995/f7711d60f805/ijms-23-09604-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e00/9455995/c2479f70b4d1/ijms-23-09604-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e00/9455995/f7711d60f805/ijms-23-09604-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e00/9455995/c2479f70b4d1/ijms-23-09604-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e00/9455995/f7711d60f805/ijms-23-09604-g002.jpg

相似文献

1
Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review.单克隆抗体工程和设计调节 FcRn 活性:全面综述。
Int J Mol Sci. 2022 Aug 24;23(17):9604. doi: 10.3390/ijms23179604.
2
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.糖基化和蛋白质-Fc联合工程同时增强治疗性抗体的细胞毒性和半衰期。
MAbs. 2014 Mar-Apr;6(2):422-36. doi: 10.4161/mabs.27854. Epub 2014 Jan 15.
3
Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?内体运输参数是否比 FcRn 结合亲和力更能成为改善单抗药代动力学的目标?
Mol Immunol. 2013 Dec;56(4):660-74. doi: 10.1016/j.molimm.2013.05.008. Epub 2013 Aug 2.
4
pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.pH 依赖性结合工程揭示了一个控制 IgG 循环的 FcRn 亲和力阈值。
J Biol Chem. 2015 Feb 13;290(7):4282-90. doi: 10.1074/jbc.M114.603712. Epub 2014 Dec 23.
5
Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization.通过 Fc 工程化和聚合增强 FcRn 依赖性跨上皮 IgG 传递。
J Control Release. 2016 Feb 10;223:42-52. doi: 10.1016/j.jconrel.2015.12.033. Epub 2015 Dec 21.
6
Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.具有相同 Fc 序列的单克隆抗体可以与 FcRn 以不同的方式结合,从而产生药代动力学后果。
Drug Metab Dispos. 2011 Sep;39(9):1469-77. doi: 10.1124/dmd.111.039453. Epub 2011 May 24.
7
Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.新生儿 FcR 在调节含有人 IgG1 Fc 结构域的治疗性蛋白血清半衰期中的重要性:单克隆抗体和 Fc 融合蛋白与人新生儿 FcR 亲和力的比较研究。
J Immunol. 2010 Feb 15;184(4):1968-76. doi: 10.4049/jimmunol.0903296. Epub 2010 Jan 18.
8
Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.新生儿Fc受体(FcRn):治疗性抗体和抗体工程的新靶点。
J Drug Target. 2014 May;22(4):269-78. doi: 10.3109/1061186X.2013.875030. Epub 2014 Jan 9.
9
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.一种预测新生儿Fc受体介导的人IgG半衰期的新型体外试验。
MAbs. 2015;7(5):912-21. doi: 10.1080/19420862.2015.1054585.
10
Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice.FcRn 结合亲和力对治疗性抗体在小鼠中皮下生物利用度的影响。
MAbs. 2012 Jan-Feb;4(1):101-9. doi: 10.4161/mabs.4.1.18543.

引用本文的文献

1
Nanobodies in animal infectious disease control: diagnosis and therapy.动物传染病防控中的纳米抗体:诊断与治疗
Front Cell Infect Microbiol. 2025 Jul 25;15:1640352. doi: 10.3389/fcimb.2025.1640352. eCollection 2025.
2
Light Chain Isotype and Antibody-Specificity Impact on Virus Neutralization.轻链同种型和抗体特异性对病毒中和作用的影响。
Antibodies (Basel). 2025 Jun 17;14(2):50. doi: 10.3390/antib14020050.
3
Exploring the Interplay Between Radioimmunoconjugates and Fcγ Receptors in Genetically Engineered Mouse Models of Cancer.

本文引用的文献

1
Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study.巴托利单抗治疗中国全身型重症肌无力患者的疗效:一项双盲、随机、安慰剂对照的II期研究。
Neurol Ther. 2022 Jun;11(2):815-834. doi: 10.1007/s40120-022-00345-9. Epub 2022 Apr 12.
2
Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.慢性自身免疫性脱髓鞘性神经病的治疗性单克隆抗体治疗。
Neurotherapeutics. 2022 Apr;19(3):874-884. doi: 10.1007/s13311-022-01222-x. Epub 2022 Mar 28.
3
Efgartigimod: First Approval.
在基因工程小鼠癌症模型中探索放射免疫偶联物与Fcγ受体之间的相互作用
ACS Pharmacol Transl Sci. 2024 Oct 17;7(11):3452-3461. doi: 10.1021/acsptsci.4c00275. eCollection 2024 Nov 8.
4
Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy.变革癌症治疗:免疫疗法的最新进展
Biomedicines. 2024 Sep 23;12(9):2158. doi: 10.3390/biomedicines12092158.
5
Living in LALA land? Forty years of attenuating Fc effector functions.生活在幻想世界?四十年的Fc效应功能衰减
Immunol Rev. 2024 Nov;328(1):422-437. doi: 10.1111/imr.13379. Epub 2024 Aug 19.
6
Single-Domain Antibodies as Antibody-Drug Conjugates: From Promise to Practice-A Systematic Review.作为抗体药物偶联物的单域抗体:从前景到实践——一项系统综述
Cancers (Basel). 2024 Jul 27;16(15):2681. doi: 10.3390/cancers16152681.
7
Monoclonal Antibodies Engineered with Fc Region Mutations to Extend Protection against Fentanyl Toxicity.工程化 Fc 区突变的单克隆抗体以延长对抗芬太尼毒性的保护作用。
J Immunol. 2024 Sep 1;213(5):663-668. doi: 10.4049/jimmunol.2400170.
8
Antibody-Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs.抗体药物偶联物:从传统构建体到下一代构建体的动态演变
Cancers (Basel). 2024 Jan 20;16(2):447. doi: 10.3390/cancers16020447.
9
Two in one: the emerging concept of bifunctional antibodies.双功能抗体:新兴概念
Curr Opin Biotechnol. 2024 Feb;85:103050. doi: 10.1016/j.copbio.2023.103050. Epub 2023 Dec 23.
10
Matrixed CDR grafting: A neoclassical framework for antibody humanization and developability.基质化 CDR 嫁接:抗体人源化和可开发性的新古典框架。
J Biol Chem. 2024 Jan;300(1):105555. doi: 10.1016/j.jbc.2023.105555. Epub 2023 Dec 10.
依氟鸟氨酸:首次批准。
Drugs. 2022 Feb;82(3):341-348. doi: 10.1007/s40265-022-01678-3.
4
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.Sotrovimab 对 SARS-CoV-2 中和抗体用于治疗新型冠状病毒早期感染。
N Engl J Med. 2021 Nov 18;385(21):1941-1950. doi: 10.1056/NEJMoa2107934. Epub 2021 Oct 27.
5
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial.以新生儿 Fc 受体抑制剂 efgartigimod 治疗寻常型天疱疮和落叶型天疱疮:一项 II 期多中心、开放性可行性试验。
Br J Dermatol. 2022 Mar;186(3):429-439. doi: 10.1111/bjd.20782. Epub 2021 Nov 28.
6
"Ways in which the neonatal Fc-receptor is involved in autoimmunity".新生儿Fc受体参与自身免疫的方式
J Transl Autoimmun. 2021 Sep 11;4:100122. doi: 10.1016/j.jtauto.2021.100122. eCollection 2021.
7
The Dual Targeting of FcRn and FcγRs Monomeric Fc Fragments Results in Strong Inhibition of IgG-Dependent Autoimmune Pathologies.FcRn 和 FcγRs 的双重靶向导致单体 Fc 片段强烈抑制 IgG 依赖性自身免疫病理学。
Front Immunol. 2021 Aug 26;12:728322. doi: 10.3389/fimmu.2021.728322. eCollection 2021.
8
Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial.新型抗白细胞介素-17单克隆抗体奈他奇单抗治疗中度至重度斑块状银屑病患者的疗效和安全性:一项为期54周的随机双盲安慰剂对照PLANETA临床试验结果
Dermatol Ther (Heidelb). 2021 Aug;11(4):1319-1332. doi: 10.1007/s13555-021-00554-4. Epub 2021 May 31.
9
In Translation: FcRn across the Therapeutic Spectrum.在治疗谱中:FcRn。
Int J Mol Sci. 2021 Mar 17;22(6):3048. doi: 10.3390/ijms22063048.
10
Antibodies to watch in 2021.2021 年值得关注的抗体药物
MAbs. 2021 Jan-Dec;13(1):1860476. doi: 10.1080/19420862.2020.1860476.